Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
You may also be interested in...
Urotronic set to complete a $20m series C, bringing its total funding to $61m for the development of drug-eluting balloon-based urology products.
Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations.
The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.